Alto Neuroscience’s recent acquisition of ALTO-207, described as an ‘intriguing asset’ by William Blair, has garnered attention for its impressive efficacy in the PAX-D study. While pramipexole showed promise, concerns about functional unblinding in the study have been raised, potentially impacting the perceived efficacy. This move highlights the company’s commitment to expanding its portfolio in […]